Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 -0.54%76 ROC (Joel Greenblatt) % is 61.21% as of Dec. 2025, which is 52% above its 10-year median of 40.39. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$461.65 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 982 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 87.68% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Lotus Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 61.21%.
The historical rank and industry rank for Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TPE:1795'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.38 Med: 40.39 Max: 70.42
Current: 59.26
During the past 13 years, Lotus Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 70.42%. The lowest was 14.38%. And the median was 40.39%.
TPE:1795's ROC (Joel Greenblatt) % is ranked better than 87.68% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs TPE:1795: 59.26
Lotus Pharmaceutical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 7.40% per year.
Lotus Pharmaceutical Co (TPE:1795) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Lotus Pharmaceutical Co ROC (Joel Greenblatt) % Related Terms
Lotus Pharmaceutical Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co ROC (Joel Greenblatt) % Chart
TPE:1795 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Lotus Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 61.21% mean?
Lotus Pharmaceutical Co (TPE:1795) has a ROC (Joel Greenblatt) % of 61.21% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Lotus Pharmaceutical Co and its competitors. This is 52% above median its historical median of 40.39. Over the past decade, Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 14.38 to 70.42. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #121 out of 982 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Lotus Pharmaceutical Co's current ROC (Joel Greenblatt) % of 61.21% is 52% above median its 10-year median of 40.39. Over the past 10 years, this metric has ranged from a low of 14.38 to a high of 70.42. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Lotus Pharmaceutical Co's value of 61.21% is 434.6% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #121 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #121 out of 982 companies for ROC (Joel Greenblatt) %. This places Lotus Pharmaceutical Co in the top 12% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.45. Lotus Pharmaceutical Co's value of 61.21% is 434.6% above this benchmark. Historically, Lotus Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 14.38 to 70.42 over the past decade. While the company's 10-year median is 40.39 vs. the industry median of 11.45, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current ROC (Joel Greenblatt) % of 61.21% is 434.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current ROC (Joel Greenblatt) % is 61.21%, which is 52% above median its own 10-year median of 40.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$461.65, compared to a current price of NT$184.00 — trading 60.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 61.21%, which is 52% above median its 10-year median of 40.39 and 434.6% above the Drug Manufacturers industry median of 11.45. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current ROC (Joel Greenblatt) % is 61.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$184.00 is trading 60.1% below its estimated GF Value™ of NT$461.65.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
ROC (Joel Greenblatt) %: 61.21% (52% above median its 10-year median of 40.39)
GF Value™: NT$461.65 vs. price of NT$184.00 (60.1% below fair value)
Industry Position: 434.6% above the Drug Manufacturers median (#121 of 982)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score
Get the complete analysis for TPE:1795
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
